Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Insmed (INSM) Misses Q4 EPS by 17c; Offers FY23 ARIKAYCE Revenue Guidance
February 23, 2023 7:49 AM ESTInsmed (NASDAQ: INSM) reported Q4 EPS of ($1.21), $0.17 worse than the analyst estimate of ($1.04). Revenue for the quarter came in at $59.3 million versus the consensus estimate of $63.57 million.
Insmed continues to expect full-year 2023 global revenues for ARIKAYCE to be between $285 million and $300... More
